Scarica l'app Stockscreener
9.71
4.24%
-0.43
Pre-mercato:
9.70
-0.01
-0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Precedente Chiudi:
$10.14
Aprire:
$10.15
Volume 24 ore:
3.94M
Relative Volume:
1.80
Capitalizzazione di mercato:
$1.46B
Reddito:
-
Utile/perdita netta:
$-738.82M
Rapporto P/E:
-1.3951
EPS:
-6.9602
Flusso di cassa netto:
$-610.15M
1 W Prestazione:
+1.04%
1M Prestazione:
-0.92%
6M Prestazione:
+16.43%
1 anno Prestazione:
-57.07%
Intervallo 1D:
$9.125
$10.78
Intervallo di 1 settimana:
$8.95
$10.78
Portata 52W:
$7.48
$22.22
Biohaven Ltd Stock (BHVN) Company Profile
Nome
Biohaven Ltd
Settore
Industria
Telefono
203-404-0410
Indirizzo
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
9.71 | 1.46B | 0 | -738.82M | -610.15M | -6.9602 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-13 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-06 | Iniziato | Goldman | Buy |
| 2026-01-21 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-12-03 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-11-26 | Downgrade | UBS | Buy → Neutral |
| 2025-11-06 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2025-11-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-09-17 | Iniziato | Citigroup | Buy |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2024-09-16 | Iniziato | Jefferies | Buy |
| 2024-09-04 | Iniziato | Bernstein | Outperform |
| 2024-07-24 | Iniziato | Morgan Stanley | Overweight |
| 2024-02-16 | Iniziato | RBC Capital Mkts | Outperform |
| 2024-02-06 | Iniziato | UBS | Buy |
| 2023-12-22 | Iniziato | H.C. Wainwright | Buy |
| 2023-12-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-01-24 | Iniziato | SVB Securities | Outperform |
| 2023-01-04 | Iniziato | JP Morgan | Overweight |
| 2022-12-02 | Iniziato | BTIG Research | Buy |
| 2022-10-26 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2022-10-12 | Iniziato | Piper Sandler | Overweight |
| 2022-08-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-05-11 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-19 | Ripresa | Morgan Stanley | Equal-Weight |
| 2021-08-10 | Downgrade | UBS | Buy → Neutral |
| 2021-08-03 | Reiterato | Canaccord Genuity | Buy |
| 2021-03-11 | Iniziato | UBS | Buy |
| 2020-12-15 | Iniziato | H.C. Wainwright | Buy |
| 2020-04-17 | Iniziato | Cowen | Outperform |
| 2020-02-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2019-11-22 | Iniziato | Wedbush | Outperform |
| 2019-06-25 | Reiterato | Canaccord Genuity | Buy |
| 2019-05-06 | Iniziato | Goldman | Buy |
| 2019-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-03-04 | Reiterato | Needham | Buy |
| 2018-07-03 | Reiterato | Needham | Buy |
| 2018-07-02 | Reiterato | Needham | Buy |
| 2018-04-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2018-02-22 | Reiterato | Canaccord Genuity | Buy |
| 2017-12-15 | Iniziato | Canaccord Genuity | Buy |
| 2017-10-03 | Reiterato | Needham | Buy |
Mostra tutto
Biohaven Ltd Borsa (BHVN) Ultime notizie
Biohaven Warns of Broad Operational, Financial and Market Risks, Affirms Overall Risk Profile Matches Prior 10-K Disclosures - TipRanks
Biohaven Expands At-The-Market Equity Offering Program - TipRanks
Biohaven (NYSE: BHVN) adds $350.0 million at-the-market share program - Stock Titan
Biohaven Ltd. (BHVN) upgraded to buy: Here's why - MSN
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's Why - Yahoo Finance Australia
Biohaven: Buy Rating Reiterated as Analyst Sees Multiple Pipeline Catalysts and Maintains $21 Price Target - TipRanks
RBC Capital Maintains Biohaven(BHVN.US) With Buy Rating, Cuts Target Price to $22 - Moomoo
Biohaven Ltd. Q1 2026 Financial Report: Key Highlights, Financial Statements, and Business Overview - Minichart
RBC Cuts Price Target on Biohaven to $22 From $23, Keeps Outperform, Speculative Risk - marketscreener.com
MSN Money - MSN
BofA Securities Maintains Biohaven(BHVN.US) With Hold Rating, Cuts Target Price to $12 - Moomoo
Biohaven Price Target Trimmed to $12 as Analyst Maintains Hold Amid Balanced Pipeline Upside and Financing Risks - TipRanks
Biohaven (BHVN) Is Up 5.7% After Narrower Q1 Loss And Pivotal Trial Plans – Has The Bull Case Changed? - simplywall.st
Biohaven Shareholders Back Board, Auditor and Executive Pay - TipRanks
Biohaven files for offering of up to $350 million common sharesSEC filing - marketscreener.com
Biohaven Ltd. (NYSE: BHVN) expands ATM program to $350M for common shares - Stock Titan
Biohaven (NYSE: BHVN) trims Q1 2026 loss and raises $178.9M - Stock Titan
Biohaven Pharma (BHVN) files mixed shelf - StreetInsider
Biohaven Ltd files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Biohaven Ltd. (NYSE: BHVN) files shelf to register shares, debt and warrants - Stock Titan
Earnings Flash (BHVN) Biohaven Ltd. Posts Q1 Adjusted Loss $0.69 per Share, Vs. FactSet Est of $-0.83 - Moomoo
Biohaven Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Biohaven (NYSE: BHVN) cuts Q1 2026 loss while funding late-stage drug pipeline - Stock Titan
Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results - ChartMill
Biohaven (NYSE: BHVN) shareholders back directors, auditors and pay plan - Stock Titan
Assessing Biohaven (BHVN) Valuation After Prolonged Share Price Weakness And Elevated P/B Ratio - simplywall.st
Biohaven Faces Catalyst-Rich 2H 2026 With Multiple Key Readouts Ahead - RTTNews
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - Stock Titan
Director at Biohaven (NYSE: BHVN) receives 68,693 stock options award - Stock Titan
Director Julia P. Gregory awarded 68,693 Biohaven (BHVN) stock options - Stock Titan
(BHVN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
BTIG Reiterates Biohaven (BHVN) Buy Recommendation - MSN
Biohaven (NYSE:BHVN) Trading Up 5.2%Here's What Happened - MarketBeat
BHVN Stock Price, Quote & Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Biohaven Obesity Trial Milestone Puts Focus On Taldefgrobep And Valuation Gap - simplywall.st
Biohaven (NYSE:BHVN) Lowered to Strong Sell Rating by Wall Street Zen - MarketBeat
Biohaven (BHVN) Short Interest & Short Float | Updated Apr 2026 - MarketBeat
Assessing Biohaven (BHVN) Valuation After Sharp One Month Rebound And Steep One Year Decline - simplywall.st
Biohaven Completes Enrollment for Obesity Drug Phase 2 Trial - HarianBasis.co
Moderate Buy Rating Seen For Biohaven Ltd. (BHVN) - Insider Monkey
Spinocerebellar Ataxias Pipeline Advances Toward - openPR.com
Biohaven (NYSE:BHVN) Shares Down 5.7%What's Next? - MarketBeat
Biohaven (BHVN) fuels confidence with encouraging azetukalner data - MSN
Canaccord Initiates Coverage of Biohaven Ltd. (BHVN) With a Buy Rating - Insider Monkey
Responsive Playbooks and the BHVN Inflection - Stock Traders Daily
Here is why Biohaven (BHVN) is among the top healthcare stocks insiders are buying - MSN
Biohaven (NYSE:BHVN) Upgraded by Wall Street Zen to Sell Rating - MarketBeat
Why Biohaven (BHVN) Is Up 10.6% After Bullish Analyst Coverage Of Late-Stage Pipeline Prospects - Sahm
Biohaven Receives 'Moderate Buy' Rating from Analysts - National Today
Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026 (BHVN) - Seeking Alpha
Biohaven Ltd Azioni (BHVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):